Monday, Oct 18, 2021 - 06:23:35
55 results - (0.000 seconds)

Merck’s drug:

mail: [NewsMag]

latest news at page 1:
12
    (CNN)During the global scramble to secure vaccines, many countries in Asia-Pacific were slow off the mark. This time, they're not making the same mistake.Countries around the region are rushing to place orders for the latest weapon against Covid-19: an antiviral pill that isn't even authorized for use yet. Molnupiravir -- produced by US pharmaceutical company Merck -- is being heralded...
    WASHINGTON (AP) — The Food and Drug Administration said Thursday it will ask its outside experts to meet in late November to scrutinize Merck’s pill to treat COVID-19. The Nov. 30 meeting means U.S. regulators almost certainly won’t issue a decision on the drug until December, signaling that the agency will conduct a detailed review of the experimental treatment’s safety...
    The first pill shown to treat COVID-19 has moved one step closer to being available to the public.The pharmaceutical company Merck requested FDA emergency authorization Monday for their COVID-19 antiviral pill, named Molnupiravir."The drug looks quite promising and it's actually a repurposed drug," said Dr. Nevan Krogan, Director of Quantitative Biosciences Institute at UCSF. "It was initially made to fight...
    Drugmaker Merck has asked United States regulators to authorize its pill for treating the Chinese coronavirus, the Associated Press (AP) reported Monday. “If cleared by the Food and Drug Administration — a decision that could come in a matter of weeks — it would be the first pill shown to treat the illness. All other FDA-backed treatments against COVID-19 require...
    Former Food and Drug Administration chief Dr. Scott Gottlieb said Monday he faults the federal government for delays that were likely to prevent Merck’s Covid-19 pill from reaching the market until 2022. Merck on Monday submitted an application to the FDA for an Emergency Use Authorization enabling distribution of its Covid-19 drug, molnupiravir, to treat patients who have the virus....
    The pharmaceutical company Merck and their partners at Ridgeback Biotherapeutics are seeking FDA emergency use authorization for an experimental pill they developed to treat non-severe coronavirus cases. Merck announced that they are requesting the authorization for molnupiravir after a series of trials suggested that the drug reduced the risk of hospitalization and death for Covid patients by around 50 percent....
    WASHINGTON (AP) — Drugmaker Merck asked U.S. regulators Monday to authorize its pill against COVID-19 in what would add an entirely new and easy-to-use weapon to the world’s arsenal against the pandemic. If cleared by the Food and Drug Administration — a decision that could come in a matter of weeks — it would be the first pill shown to...
    MIAMI (CBSMiami/AP) – Drugmaker Merck, the company behind a COVID-19 pill that was being studied in South Florida, has filed an application with the Food and Drug Administration asking for emergency authorization of its use. If cleared by the Food and Drug Administration — a decision that could come in a matter of weeks — it would be the first...
    WASHINGTON -- Drugmaker Merck asked U.S. regulators Monday to authorize its pill against COVID-19 in what would add an entirely new and easy-to-use weapon to the world's arsenal against the pandemic.If cleared by the Food and Drug Administration - a decision that could come in a matter of weeks - it would be the first pill shown to treat COVID-19....
    (CNN) — Merck said Monday it is seeking US Food and Drug Administration emergency use authorization for its experimental antiviral Covid-19 treatment, molnupiravir. If authorization is granted, the drug, made by Merck and Ridgeback Biotherapeutics, would be the first oral antiviral treatment to fight Covid-19. It comes in capsule form. Merck said it is asking for authorization for the capsules...
    (CNN)Merck said Monday it is seeking US Food and Drug Administration emergency use authorization for its experimental antiviral Covid-19 treatment, molnupiravir.If authorization is granted, the drug, made by Merck and Ridgeback Biotherapeutics, would be the first oral antiviral treatment to fight Covid-19. It comes in capsule form.Merck said it is asking for authorization for the capsules to treat infected adults...
    The New Jersey-based pharmaceutical giant Merck is facing accusations of price gouging after it charged the U.S. over $700 per patient for a taxpayer-funded coronavirus treatment that, according to research, costs just $17.74 to produce. Last week, Merck announced plans to request emergency federal authorization for molnupiravir after a late-stage clinical trial showed that a five-day course of the antiviral...
    Former FDA Commissioner Dr. Scott Gottlieb said on Wednesday that the “pandemic phase” of Covid-19 could be nearing an end, following the approval of an antiviral drug from Merck and a vaccine for children ages 5-11. During the CNBC Squawk on the Street interview, Gottlieb suggested that many people would “get comfortable going back into the office” as those two...
    RT: Maria Van Kerkhove, Head a.i. Emerging Diseases and Zoonosis at the World Health Organization (WHO), speaks during a news conference on the situation of the coronavirus at the United Nations in Geneva, Switzerland, January 29, 2020.Denis Balibouse | Reuters Merck's announcement that its experimental antiviral pill is effective against the most severe outcomes of Covid-19 is "certainly good news,"...
    Merck announced this week a new pill to treat COVID-19 and its application for Emergency Use Authorization, which Johns Hopkins School of Public Health Dr. Amesh Adalja predicted could come to market by the end of 2021. "If everything works according to plan, meaning the emergency use authorization, robust phase three clinical data and all of the signals look good,"...
    President BidenJoe BidenProgressives hit back after moderates take aim at Pelosi John Kerry expresses optimism about upcoming climate summit Biden's Red Queen justice: How he destroyed both the investigation and the reputation of border agents MORE’s top medical adviser, Anthony FauciAnthony FauciFauci: Results from Merck pill to treat COVID-19 'impressive' Watch live: White House COVID-19 response team holds press briefing Activists...
    (CNN)A new approach to managing the Covid-19 pandemic now could be on the table: antiviral pills. On Friday, Merck and Ridgeback Biotherapeutics said their results (still not peer-reviewed) demonstrate their novel drug molnupiravir cut in half the rate of hospitalization and death in persons with mild to moderate disease. If authorized by the US Food and Drug Administration for emergency...
    MIAMI (CBSMiami) – A new breakthrough pill for treating people with Covid that was tested in South Florida may be available in a couple of months. The drug maker Merck is seeking emergency use authorization for the pill known as Molnupiravir. READ MORE: Miami Mayoral Candidate Frank Pichel Facing Felony Charge Of Impersonating Police OfficerAccording to the company,...
    New Jersey drug manufacturer Merck & Co. and Ridgeback Biotherapeutics on Friday said the new experimental COVID-19 drug significantly reduces hospitalization time and chance of death for 50 percent of patients with mild to moderate cases. In light of the new findings, the Kenilworth-based company has stopped the drug's trial to apply for emergency use authorization. Molnupiravir is an oral pill...
    PHILADELPHIA (CBS) — There’s been a potentially major advancement in the efforts to fight the coronavirus pandemic. New Jersey-based drugmaker Merck & Co. says its experimental COVID-19 pill is so effective that the trial has been halted so it can immediately apply for emergency use authorization. Merck & Co.’s drug would be the first pill to treat COVID-19. If it...
    The outlet reported that the data shows that the drug is "not capable of inducing genetic changes in human cells," though it warned male patients in the trial to abstain from heterosexual intercourse or agree to use contraception. Female participants of childbearing age were not permitted to be pregnant and also were told to use contraception. Robert Davis, Merck's CEO,...
    WASHINGTON (AP) — Merck & Co. said Friday that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the U.S. and around the world to authorize its use. If cleared, Merck’s drug would be the first pill shown to treat COVID-19, a potentially...
    KENILWORTH, New Jersey -- Merck & Co. said Friday that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the U.S. and around the world to authorize its use.If cleared, Merck's drug would be the first pill shown to treat COVID-19, a potentially...
    WASHINGTON (AP) — Merck & Co. said Friday that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the U.S. and around the world to authorize its use. If cleared, Merck’s drug would be the first pill shown to treat COVID-19, a potentially...
    In this article MRKA nurse tends to a Covid-19 patient at SSM Health St. Anthony Hospital in Oklahoma City, August 24, 2021.Nick Oxford | ReutersMerck and Ridgeback Biotherapeutics plan to seek emergency authorization for their oral antiviral treatment for Covid-19, after the medicine showed "compelling results" in clinical trials. The drug, molnupiravir, reduced the risk of hospitalization or death by...
    Pharmaceutical company Merck announced Wednesday that its oral experimental COVID-19 drug is likely to be effective against multiple strains, including the delta variant, Reuters reported. The company said that its new drug, molnupiravir, targets the enzyme that allows the virus to replicate itself by introducing errors in the virus’s genetic code, Reuters reported.  The treatment works best in those with...
    You are not a horse. You are not a cow. Seriously, y'all. Stop it. https://t.co/TWb75xYEY4 — U.S. FDA (@U.S. FDA)1629547061.0 Evidently, officials believe that millions of human beings in Africa (not to mention thousands in the Western world) are no better than animals. Ivermectin has been dispensed 3.7 billion times in African countries since 1987 and is regarded as one...
    Photo: Chokniti Khongchum / Pexels The biopharmaceutical company Merck Sharp & Dohme (MSD) announced that seven research centers in Mexico are recruiting Covid-19 patients for phase 2/3 clinical trial of an antiviral drug orally administered, which prevents virus replication and has the potential for action on several RNA viruses, including SARS-CoV-2. The clinical tests will include...
    Merck’s second-quarter profit dove 49%, mainly due to a big charge for an acquisition and a higher tax rate, though sales of its vaccines and medicines used in hospitals rebounded from the effects of the pandemic. Merck & Co. on Thursday reported second-quarter net income of $1.55 billion. On a per-share basis, the Kenilworth, New Jersey-based company said it had...
    VIDEO2:0702:07Merck says its Covid pill shows promise for non-hospitalized patientsSquawk Box Merck announced Thursday it will end the development of its experimental drug for patients hospitalized with severe Covid-19 after the Food and Drug Administration asked the company to provide additional data to support an emergency use authorization. New Jersey-based Merck acquired the drug, MK-7110, through its $425 million acquisition...
    To fight Covid-19, it’s not just vaccination. Researchers are also working hard to find an effective treatment to cure the sick. Progress sparking hope Since its discovery over a year ago, the Covid-19 continues to progress. Today, the world is focused on vaccination, but when it comes to the fight against this contagious disease, it is not just the vaccine....
    For William Fischer, one of the directors of the research and professor of medicine at the University of North Carolina, the results of phase two of molnupiravir are promising. “If they are reinforced with additional studies, they could have important consequences in terms of public health, as the virus continues to spread and evolve in the world,” he...
    Experimental antiviral drug molnupiravir being developed by New Jersey drug manufacturer Merck with Ridgeback Bio shows a quick reduction of the infectious virus in a study among participants with early COVID-19. Molnupiravir is being tested in a Phase 2/3 trial set to be completed in May. Merck will be provided with up to  $268.8 million in funding from the Biomedical Advanced Research and Development...
    (Reuters) - U.S. drugmaker Merck & Co Inc said on Saturday the experimental antiviral drug molnupiravir it is developing with Ridgeback Bio showed a quicker reduction in infectious virus in its phase 2a study among participants with early COVID-19. "The secondary objective findings in this study, of a quicker decrease in infectious virus among individuals with early COVID-19 treated with...
    WASHINGTON - U.S. pharmaceutical giant Merck has agreed to help manufacture rival Johnson & Johnson’s new coronavirus vaccine to help speed production of millions of new doses of the single shots to inoculate more Americans in the coming months, White House officials said Tuesday. Johnson & Johnson has encountered unexpected production problems, even as it won emergency use approval...
    By Dan Levine and Chad Terhune (Reuters) - Newly unsealed court documents and other records show that Merck & Co and U.S. regulators knew about reports of suicidal behavior in men taking the company’s anti-baldness treatment Propecia when they decided not to warn consumers of those potential risks in a 2011 update of the popular drug’s label. Internal records from...
    Merck is pulling the plugs on two potential COVID-19 vaccines following poor results in early-stage studies. The drugmaker said Monday it will focus instead on studying two possible treatments for the virus that also have yet to be approved by regulators.  Merck said its potential vaccines were well tolerated by patients, but they generated an inferior immune system response compared...
    Ciryl Gane wont call out rivals, but admits Jairzinho Rozenstruik bout makes sense Architectural homes for sale across America Pfizer to Supply U.S. With 100 Million More Vaccine Doses (Bloomberg) -- Pfizer Inc. and partner BioNTech SE agreed to supply an additional 100 million doses of their Covid-19 vaccine to the U.S., as the country seeks to widen its...
12